INO Share Price

Open 6.27 Change Price %
High 6.28 1 Day -0.77 -11.36
Low 6.00 1 Week -1.95 -24.50
Close 6.01 1 Month -2.05 -25.43
Volume 15768445 1 Year -3.04 -33.59
52 Week High 11.00
52 Week Low 5.83
INO Important Levels
Resistance 2 6.27
Resistance 1 6.16
Pivot 6.10
Support 1 5.86
Support 2 5.75
AMEX USA Most Active Stocks
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
INO 6.01 -11.36%
RBY 0.03 -70.00%
PBTH 8.23 0.37%
BTI 70.00 0.86%
BTI 70.00 0.86%
IMUC 0.39 11.43%
LODE 0.20 5.26%
More..
AMEX USA Top Gainers Stocks
GGR 0.02 100.00%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
MBA 0.20 25.00%
MBA 0.20 25.00%
MBA 0.20 25.00%
IG 7.68 22.49%
IG 7.68 22.49%
More..
AMEX USA Top Losers Stocks
RBY 0.03 -70.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
QBC 0.20 -33.33%
ATL 0.06 -25.00%
ATL 0.06 -25.00%
TPLM 0.03 -25.00%
SNT 0.12 -20.00%
INV 0.14 -17.65%
More..

Inovio Pharmaceuticals, Inc. (AMEX: INO)

INO Technical Analysis 5
As on 20th Jul 2017 INO Share Price closed @ 6.01 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 7.42 & Strong Sell for SHORT-TERM with Stoploss of 7.58 we also expect STOCK to react on Following IMPORTANT LEVELS.
INO Target for July
1st Target up-side 8.59
2nd Target up-side 9.12
3rd Target up-side 9.65
1st Target down-side 7.09
2nd Target down-side 6.56
3rd Target down-side 6.03
INO Other Details
Segment EQ
Market Capital 89092640.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.inovio.com
INO Address
INO
Building 18
Suite 400
Blue Bell, PA 19422
United States
Phone: 267-440-4200
Fax: 267-440-4242
Interactive Technical Analysis Chart Inovio Pharmaceuticals, Inc. ( INO AMEX USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Inovio Pharmaceuticals, Inc.
INO Business Profile
Inovio Pharmaceuticals, Inc., together with its subsidiaries, discovers, develops, and develops synthetic vaccines and immune therapies focusing on cancers and infectious diseases. The company’s DNA-based SynCon technology designed to provide protection against known and new unmatched strains of pathogens, such as influenza. Its electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company’s clinical programs include HPV-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, and malaria vaccines. It is also advancing preclinical research for a seasonal/pandemic influenza vaccine, as well as other products. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. in May 2010. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Blue Bell, Pennsylvania.